The authors of "KMT2D Deficiency Promotes Myeloid Leukemias which…" (https://t.co/4FnXQeQNCt) included RRIDs in their paper! Thank you for making your #methodsmatter. #accelerateopenscience
KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis Inhibition.
Mentions
Extended reach
Total likes
Video views
Mentions per month
May 2023 – Oct 2023Where it's discussed
-
X / Twitter1 posts
-
YouTube1 videos
AI synopsis
What people are saying
The discussion is very limited, focusing solely on the inclusion of RRIDs and open science practices, which suggests some appreciation for methodological clarity but little interest in the broader scientific implications of the research. The tone is appreciative but lacks depth or critical analysis, contributing to the neutral scores across agreement and impact.
The single post expresses appreciation for the authors including RRIDs, aligning with open science practices, but overall, there is limited discussion on the article's findings, leading to a neutral agreement score.
The post shows some interest by acknowledging methodological transparency, indicating a mild engagement with the article's content.
The discussion reflects a basic recognition of the authors' transparency, but lacks deep analysis or engagement with the implications of the research findings.
The reply highlights a positive aspect of the publication (method transparency), but because there is only one post, the perceived overall impact on the community is minimal.
Abstract in brief
- KMT2D is often mutated or downregulated in acute myeloid leukemia (AML), and its loss accelerates leukemia development by increasing ribosome production and cell growth.
- The deficiency of KMT2D activates the mTOR pathway, which promotes abnormal ribosome biogenesis through the regulation of the gene Ddit4.
- Targeting ribosome production with a drug called CX5461 can effectively slow down AML growth and improve survival in mice with KMT2D loss, highlighting a potential treatment strategy.]
Top posts
Most liked on X and BlueskyAll mentions
KMT2D Loss Exacerbates Leukemia and Vulnerability to Ribosome Inhibition
KMT2D deficiency accelerates acute myeloid leukemia development by increasing ribosome biogenesis and activating the mTOR pathway. The drug CX5461 effectively inhibits ribosome production, reducing leukemia growth and…
The authors of "KMT2D Deficiency Promotes Myeloid Leukemias which…" (https://t.co/4FnXQeQNCt) included RRIDs in their paper! Thank you for making your #methodsmatter. #accelerateopenscience
RR